FI70208C - Foerfarande foer framstaellning av nya terapeutiskt anvaendbara n-acetyl-para-aminofenyl-n'-acetyl aminotioalkansyraesterderivat - Google Patents
Foerfarande foer framstaellning av nya terapeutiskt anvaendbara n-acetyl-para-aminofenyl-n'-acetyl aminotioalkansyraesterderivat Download PDFInfo
- Publication number
- FI70208C FI70208C FI781610A FI781610A FI70208C FI 70208 C FI70208 C FI 70208C FI 781610 A FI781610 A FI 781610A FI 781610 A FI781610 A FI 781610A FI 70208 C FI70208 C FI 70208C
- Authority
- FI
- Finland
- Prior art keywords
- acetyl
- para
- napa
- compound
- aminophenyl
- Prior art date
Links
- 150000002148 esters Chemical class 0.000 title claims description 13
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 224
- 238000002360 preparation method Methods 0.000 claims description 23
- 150000001875 compounds Chemical class 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 21
- 239000002253 acid Substances 0.000 claims description 18
- 150000008064 anhydrides Chemical class 0.000 claims description 18
- 125000006239 protecting group Chemical group 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical compound NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 150000002989 phenols Chemical class 0.000 claims description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 2
- GRDMQWRBLJZFML-UHFFFAOYSA-N bis(4-nitrophenyl) sulfite Chemical compound C1=CC([N+](=O)[O-])=CC=C1OS(=O)OC1=CC=C([N+]([O-])=O)C=C1 GRDMQWRBLJZFML-UHFFFAOYSA-N 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 229940126062 Compound A Drugs 0.000 description 50
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 50
- 239000000203 mixture Substances 0.000 description 39
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 37
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- 239000005862 Whey Substances 0.000 description 27
- 102000007544 Whey Proteins Human genes 0.000 description 27
- 108010046377 Whey Proteins Proteins 0.000 description 27
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 22
- 108010024636 Glutathione Proteins 0.000 description 19
- 229960003180 glutathione Drugs 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 241000700159 Rattus Species 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000003556 assay Methods 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 229960001701 chloroform Drugs 0.000 description 12
- 229930182817 methionine Natural products 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 230000000202 analgesic effect Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 239000002207 metabolite Substances 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 210000000548 hind-foot Anatomy 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 210000005229 liver cell Anatomy 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- -1 sulfhydryl compound Chemical class 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- 208000000114 Pain Threshold Diseases 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 230000006399 behavior Effects 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 230000037040 pain threshold Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 244000215068 Acacia senegal Species 0.000 description 4
- 108090000371 Esterases Proteins 0.000 description 4
- 229920000084 Gum arabic Polymers 0.000 description 4
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 4
- 206010067125 Liver injury Diseases 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000000205 acacia gum Substances 0.000 description 4
- 235000010489 acacia gum Nutrition 0.000 description 4
- 230000007059 acute toxicity Effects 0.000 description 4
- 231100000403 acute toxicity Toxicity 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 231100000234 hepatic damage Toxicity 0.000 description 4
- 230000008818 liver damage Effects 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 230000001754 anti-pyretic effect Effects 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 150000002431 hydrogen Chemical group 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000012258 stirred mixture Substances 0.000 description 3
- 150000003512 tertiary amines Chemical class 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 125000003047 N-acetyl group Chemical group 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000538 analytical sample Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 229930182480 glucuronide Natural products 0.000 description 2
- 150000008134 glucuronides Chemical class 0.000 description 2
- 230000002631 hypothermal effect Effects 0.000 description 2
- 229960001913 mecysteine Drugs 0.000 description 2
- 229960003151 mercaptamine Drugs 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 2
- 231100000499 nonhepatotoxic Toxicity 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000013097 stability assessment Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 150000003527 tetrahydropyrans Chemical class 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- IUOAGMMAQBPUHE-IENPIDJESA-N (2r)-2-acetamido-3-(oxan-2-ylsulfanyl)propanoic acid Chemical compound CC(=O)N[C@H](C(O)=O)CSC1CCCCO1 IUOAGMMAQBPUHE-IENPIDJESA-N 0.000 description 1
- RYGLCORNOFFGTB-YFKPBYRVSA-N (2r)-2-acetamido-3-methylsulfanylpropanoic acid Chemical compound CSC[C@@H](C(O)=O)NC(C)=O RYGLCORNOFFGTB-YFKPBYRVSA-N 0.000 description 1
- MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 description 1
- 102000009133 Arylsulfatases Human genes 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 101100285402 Danio rerio eng1a gene Proteins 0.000 description 1
- 208000031969 Eye Hemorrhage Diseases 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000237369 Helix pomatia Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- DVPRQNKJGQEICH-JTQLQIEISA-N S-(5-acetamido-2-hydroxyphenyl)-N-acetyl-L-cysteine Chemical compound CC(=O)N[C@H](C(O)=O)CSC1=CC(NC(C)=O)=CC=C1O DVPRQNKJGQEICH-JTQLQIEISA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical class C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 239000012345 acetylating agent Substances 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 239000003849 aromatic solvent Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- QSKWJTXWJJOJFP-UHFFFAOYSA-N chloroform;ethoxyethane Chemical compound ClC(Cl)Cl.CCOCC QSKWJTXWJJOJFP-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-L cysteinate(2-) Chemical compound [S-]CC(N)C([O-])=O XUJNEKJLAYXESH-UHFFFAOYSA-L 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 229960001051 dimercaprol Drugs 0.000 description 1
- WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940111688 monobasic potassium phosphate Drugs 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229940099459 n-acetylmethionine Drugs 0.000 description 1
- ZHCAAFJSYLFLPX-UHFFFAOYSA-N nitrocyclohexatriene Chemical group [O-][N+](=O)C1=CC=C=C[CH]1 ZHCAAFJSYLFLPX-UHFFFAOYSA-N 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 108060007951 sulfatase Proteins 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 231100000563 toxic property Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB22218/77A GB1583602A (en) | 1977-05-26 | 1977-05-26 | N-acetyl-para-aminophenyl-n'-acetyl-amino-thioalkanoic acid ester derivatives |
| GB2221877 | 1977-05-26 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI781610A7 FI781610A7 (fi) | 1978-11-27 |
| FI70208B FI70208B (fi) | 1986-02-28 |
| FI70208C true FI70208C (fi) | 1986-09-15 |
Family
ID=10175844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI781610A FI70208C (fi) | 1977-05-26 | 1978-05-22 | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara n-acetyl-para-aminofenyl-n'-acetyl aminotioalkansyraesterderivat |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US4181719A (de) |
| AT (1) | AT368489B (de) |
| BE (1) | BE867531A (de) |
| CH (1) | CH644590A5 (de) |
| DE (1) | DE2822789C2 (de) |
| DK (1) | DK155832C (de) |
| FI (1) | FI70208C (de) |
| FR (1) | FR2391998A1 (de) |
| GB (1) | GB1583602A (de) |
| IE (1) | IE47072B1 (de) |
| IT (1) | IT1202822B (de) |
| LU (1) | LU79703A1 (de) |
| NL (1) | NL176070C (de) |
| NO (1) | NO146392C (de) |
| SE (1) | SE448991B (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1111384B (it) * | 1978-12-21 | 1986-01-13 | Sigma Tau Ind Farmaceuti | Guaiacil esteri di derivati dello acido mercaptopropionico procedimento per la loro preparazione e loro uso terapeutico |
| US4307073A (en) * | 1980-08-08 | 1981-12-22 | The Research Foundation Of State University Of New York | Method and composition for reducing the toxicity of acetaminophen |
| US4504413A (en) * | 1982-04-02 | 1985-03-12 | Syva Company | Acetaminophen analogs, antigens, and antibodies |
| US4605754A (en) * | 1982-04-02 | 1986-08-12 | Syntex (U.S.A.) Inc. | Acetaminophen analogs |
| US5103021A (en) * | 1982-04-02 | 1992-04-07 | Syntex (U.S.A.) Inc. | Acetaminophen analogs, antigens, and antibodies |
| CH654302A5 (de) * | 1983-05-04 | 1986-02-14 | Sandoz Ag | Acylaminophenolderivate, ihre herstellung und arzneimittel, welche sie enthalten. |
| GB9305058D0 (en) * | 1993-03-12 | 1993-04-28 | Penn Pharm Ltd | Pharmaceutical compositions |
| DE19711053C2 (de) * | 1997-03-03 | 1999-09-02 | Rommelspacher | Kombinationspräparat aus 2-Methyl-thiazolidin-2,4-dicarbonsäure und Paracetamol |
| FR2814366A1 (fr) * | 2000-09-22 | 2002-03-29 | Rhodia Chimie Sa | Procede de granulation de matieres actives par extrusion basse pression pour l'obtention de granules directement compressibles |
| WO2002036077A2 (en) * | 2000-11-06 | 2002-05-10 | Andrx Pharmaceuticals, Inc. | Once a day antihistamine and decongestant formulation |
| GB0114069D0 (en) * | 2001-06-08 | 2001-08-01 | Smithkline Beecham Plc | Composition |
| US8092831B2 (en) * | 2002-11-08 | 2012-01-10 | Andrx Pharmaceuticals, Llc | Antihistamine and decongestant system |
| WO2004045551A2 (en) * | 2002-11-15 | 2004-06-03 | Branded Products For The Future | Pharmaceutical composition |
| US20050220862A1 (en) * | 2004-03-31 | 2005-10-06 | Bernstein Joel E | Compositions with reduced hepatotoxicity |
| WO2009138437A1 (en) * | 2008-05-13 | 2009-11-19 | Genmedica Therapeutics Sl | Salicylate conjugates useful for treating metabolic disorders |
| EP2285419A4 (de) * | 2008-05-20 | 2012-05-02 | Neurogesx Inc | Leberschützende mutuale paracetamol-prodrugs |
| US20100239552A1 (en) * | 2009-03-16 | 2010-09-23 | Genmedica Therapeutics Sl | Combination Therapies for Treating Metabolic Disorders |
| US8575217B2 (en) * | 2009-03-16 | 2013-11-05 | Genmedica Therapeutics Sl | Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders |
| US8466197B2 (en) | 2010-12-14 | 2013-06-18 | Genmedica Therapeutics Sl | Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR462M (de) * | 1958-10-13 | 1961-05-02 | ||
| US3591686A (en) * | 1967-08-01 | 1971-07-06 | Mead Johnson & Co | Anti-inflammatory compositions and methods utilizing n-acylcysteines and the beta-alkyl and carboxyl derivatives thereof |
| US4038306A (en) * | 1967-08-07 | 1977-07-26 | Merck & Co., Inc. | N-t-butoxycarbonyl-s-lower alkanoylamidomethyl-cysteine and p-nitrophenyl esters |
| GB1428803A (en) * | 1973-05-29 | 1976-03-17 | Gallardo Antonio Sa | 4-acetamidophenyl esters of aryl-alkane carboxylic acids and a process for their preparation |
| US3983138A (en) * | 1973-09-25 | 1976-09-28 | Merck & Co., Inc. | Amino acid esters |
| GB1463505A (en) * | 1973-11-21 | 1977-02-02 | Nat Res Dev | Pharmaceutical compositions |
| US3996268A (en) * | 1974-09-03 | 1976-12-07 | The Regents Of The University Of California | Cross-linking reagent for insulin synthesis |
-
1977
- 1977-05-26 GB GB22218/77A patent/GB1583602A/en not_active Expired
-
1978
- 1978-05-22 FI FI781610A patent/FI70208C/fi not_active IP Right Cessation
- 1978-05-24 DE DE2822789A patent/DE2822789C2/de not_active Expired
- 1978-05-24 AT AT0380178A patent/AT368489B/de not_active IP Right Cessation
- 1978-05-25 NL NLAANVRAGE7805675,A patent/NL176070C/xx not_active IP Right Cessation
- 1978-05-25 DK DK231578A patent/DK155832C/da not_active IP Right Cessation
- 1978-05-25 NO NO781824A patent/NO146392C/no unknown
- 1978-05-25 LU LU79703A patent/LU79703A1/xx unknown
- 1978-05-25 IT IT49547/78A patent/IT1202822B/it active
- 1978-05-25 SE SE7806038A patent/SE448991B/sv not_active IP Right Cessation
- 1978-05-25 IE IE1047/78A patent/IE47072B1/en unknown
- 1978-05-26 BE BE188076A patent/BE867531A/xx not_active IP Right Cessation
- 1978-05-26 FR FR7815759A patent/FR2391998A1/fr active Granted
- 1978-05-26 CH CH578078A patent/CH644590A5/de not_active IP Right Cessation
- 1978-05-26 US US05/909,846 patent/US4181719A/en not_active Expired - Lifetime
-
1979
- 1979-04-02 US US06/026,329 patent/US4482495A/en not_active Expired - Lifetime
-
1981
- 1981-03-23 US US06/246,234 patent/US4361703A/en not_active Expired - Fee Related
-
1982
- 1982-03-22 US US06/360,312 patent/US4405800A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| IT7849547A0 (it) | 1978-05-25 |
| CH644590A5 (de) | 1984-08-15 |
| NL7805675A (nl) | 1978-11-28 |
| IE47072B1 (en) | 1983-12-14 |
| US4405800A (en) | 1983-09-20 |
| NL176070C (nl) | 1985-02-18 |
| BE867531A (fr) | 1978-09-18 |
| US4181719A (en) | 1980-01-01 |
| NL176070B (nl) | 1984-09-17 |
| NO146392C (no) | 1982-09-22 |
| DK155832C (da) | 1989-10-02 |
| DE2822789A1 (de) | 1978-12-07 |
| GB1583602A (en) | 1981-01-28 |
| SE448991B (sv) | 1987-03-30 |
| LU79703A1 (fr) | 1978-11-06 |
| DE2822789C2 (de) | 1984-01-12 |
| DK231578A (da) | 1978-11-27 |
| IT1202822B (it) | 1989-02-09 |
| ATA380178A (de) | 1982-02-15 |
| NO781824L (no) | 1978-11-28 |
| FR2391998B1 (de) | 1981-11-13 |
| DK155832B (da) | 1989-05-22 |
| FR2391998A1 (fr) | 1978-12-22 |
| AT368489B (de) | 1982-10-11 |
| SE7806038L (sv) | 1978-11-27 |
| FI70208B (fi) | 1986-02-28 |
| US4361703A (en) | 1982-11-30 |
| US4482495A (en) | 1984-11-13 |
| NO146392B (no) | 1982-06-14 |
| IE781047L (en) | 1978-11-26 |
| FI781610A7 (fi) | 1978-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI70208C (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara n-acetyl-para-aminofenyl-n'-acetyl aminotioalkansyraesterderivat | |
| Morris et al. | Studies of carcinogenicity in the rate of derivatives of aromatic amines related to N-2-fluorenylacetamide | |
| KR100615560B1 (ko) | 담즙산 및 담즙산 유도체의 지방산 유도체 | |
| JP4728481B2 (ja) | リポ酸誘導体および疾患の治療におけるそれら誘導体の使用 | |
| FI77249B (fi) | Foerfarande foer framstaellning av en ny antibiotisk foerening. | |
| KR100394986B1 (ko) | 비-베타-산화성지방산유사체를주성분으로하는치료용약제 | |
| US4305958A (en) | Cysteine derivatives | |
| JPS62267222A (ja) | 不飽和脂肪酸含有製剤 | |
| Sullivan et al. | Hypolipidemic activity of (−)-hydroxycitrate | |
| US6127578A (en) | Method of altering sphingolipid metabolism and detecting fumonisin ingestion and contamination | |
| Jenkins et al. | Antiketogenic and hypoglycemic effects of aminocarnitine and acylaminocarnitines. | |
| US4425360A (en) | Pharmacologically active novel O-substituted pyruvic acid oximes | |
| US4310546A (en) | Novel retinoids and their use in preventing carcinogenesis | |
| FR2479833A1 (fr) | Nouveaux derives d'acides omega-amino-carboxyliques et leur utilisation a titre de medicaments | |
| Fabre et al. | Metabolism of cyclosporin A. III. Interaction of the macrolide antibiotic, erythromycin, using rabbit hepatocytes and microsomal fractions. | |
| US5350767A (en) | Derivatives of cysteine | |
| EP1066235A1 (de) | Synthetische endogene cannabinoidanaloge und ihre verwendungen | |
| US4725588A (en) | Alkyl phospholipid antihypertensive agents in method of lowering blood pressure | |
| Gnoni et al. | Thyroid hormone stimulation of lipogenesis in isolated rat hepatocytes | |
| FI93442C (fi) | Menetelmä uusien kysteiinijohdannaisten valmistamiseksi | |
| Calabrese et al. | Effects of L-carnitine on the formation of fatty acid ethyl esters in brain and peripheral organs after short-term ethanol administration in rat | |
| WO2019052529A1 (zh) | 糖类化合物的医药用途 | |
| NAKAMURA et al. | Effect of oral pretreatment with antibiotics on the hydrolysis of salicylic acid-tyrosine and salicylic acid-methionine prodrugs in rabbit intestinal microorganisms | |
| Fukuoka et al. | Metabolism of 2-thiobenzothiazoles in the rat: Urinary, fecal and biliary metabolites of 2-benzothiazyl sulfenamides | |
| US3769436A (en) | Compositions and methods for the treatment of hyperlipemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: STERWIN AG |